A Phase 2, multicenter, open label, two parts clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 (IDH1) mutant glioma
Contact:
NCT Number:
Protocol:
AAAU6265
Study Status:
Active/Enrolling
Population:
Adult
Phase:
II
The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved.
Are you Eligible? (Inclusion Criteria)
- Must be 18 years old or older - Must have have life expectancy 3 months or more - Must have negative result for COVID
Specialty Area(s)
Brain and Spinal Tumors, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
